{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 39,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a side-by-side comparison structure to detail trial status and upcoming milestones for two distinct clinical programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/7",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "list",
      "text": "EQUALISE Phase 1b in lupus nephritis: Fully enrolled, Open-label study, interim data showed meaningful response. Milestone: Topline data expected early 2024.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04a9328c-3695-46fb-a0ec-d708e0e61d09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.38
      },
      "kind": "list",
      "text": "EQUATOR Pivotal Phase 3 in acute GVHD: Enrolling (n=200), Randomized controlled study (1:1), Phase 1B showed high response rates. Milestone: Interim Review @ 100 patients expected 2024.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a5c304f-9afb-4c1f-898b-23568c5f5818",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.68,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "Itolizumab: Two Data Deliverables Expected in 2024",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54e216e9-bbaa-4a66-acdc-74095f49094a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Driving Development Towards Ono Option Decision",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38219b4c-0426-45d9-90bc-04f3d7e4bac6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "e7dddfc4-f08d-43c8-aba1-5bea798c5a3e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented on pages 5-9.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}